###begin article-title 0
###xml 33 37 <span type="species:ncbi:10090">Mice</span>
Timed Somatic Deletion of p53 in Mice Reveals Age-Associated Differences in Tumor Progression
###end article-title 0
###begin p 1
Conceived and designed the experiments: GH LAD. Performed the experiments: GH NP. Analyzed the data: GH NP LAD. Contributed reagents/materials/analysis tools: GH. Wrote the paper: LAD.
###end p 1
###begin p 2
Current address: Unite d'Oncologie Moleculaire, Centre Leon Berard, Lyon, France
###end p 2
###begin p 3
###xml 90 95 <span type="species:ncbi:9606">human</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 398 402 <span type="species:ncbi:10090">Mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 763 767 <span type="species:ncbi:10090">mice</span>
Inactivating mutations in the p53 tumor suppressor gene occur often in the progression of human cancers. p53 inhibits the outgrowth of nascent cancer cells through anti-proliferative actions (including induction of apoptosis or senescence). To test p53 tumor suppressor functions in a novel experimental context, we somatically deleted both p53 alleles in multiple tissues of mice at various ages. Mice homozygously deleted for p53 at 3 months of age showed a longer tumor latency compared to mice deleted for p53 at 6 and 12 months of age. These results are consistent with a model in which tissues accumulate oncogenically activated cells with age and these are held in check by wildtype p53. We also deleted p53 before, concurrent with, and after treatment of mice with ionizing radiation (IR). The absence or presence of p53 during IR treatment had no effect on radiation-induced lymphoma latency, confirming that the immediate p53 damage response was irrelevant for cancer prevention. Even the presence of wildtype p53 for up to four weeks post-IR provided no protection against early lymphoma incidence, indicating that long term maintenance of functional p53 is critical for preventing the emergence of a cancer. These experiments indicate that sustained p53 anti-oncogenic function acts as a final or near final line of defense preventing progression of oncogenically activated cells to malignant tumors.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Kinzler1">[1]</xref>
###xml 371 374 371 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Levine1">[2]</xref>
###xml 376 379 376 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Soussi1">[3]</xref>
###xml 512 515 512 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Levine1">[2]</xref>
###xml 1047 1050 1047 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Kinzler1">[1]</xref>
###xml 1052 1055 1052 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Macleod1">[4]</xref>
###xml 1257 1260 1257 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Kinzler1">[1]</xref>
###xml 1262 1265 1262 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Blondal1">[5]</xref>
###xml 1267 1270 1267 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Olivier1">[6]</xref>
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 1035 1045 <span type="species:ncbi:111938">gatekeeper</span>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
Genetic, epigenetic, or functional inactivation of multiple tumor suppressor genes is a hallmark of human cancers [1]. Among the most important of the tumor suppressors is p53. The p53 gene is mutated or lost in roughly half of all human cancers, and functional inactivation of p53 signaling pathways occurs in many cancers where the p53 gene remains structurally intact [2], [3]. In response to mutagenic or oncogenic stress, p53 can induce a transient or permanent cell cycle arrest or it can induce apoptosis [2]. These anti-proliferative responses of p53 prevent the emergence of a nascent cancer cell that has been activated through aberrant oncogene signaling. Oncogenic stress may activate p53 through ARF signaling or through DNA damage signaling pathways. In the traditional colorectal multi-step cancer progression model of Kinzler and Vogelstein, mutation and loss of p53 function often occurs in the transition from the adenoma stage to the malignant carcinoma stage, leading to the categorization of p53 as a "progression gatekeeper" [1], [4]. In human cancers, p53 mutation or inactivation can be an early or late event, though it is unlikely to be an initiating event in most cancers and usually occurs during cancer evolution or progression [1], [5], [6].
###end p 5
###begin p 6
###xml 501 504 501 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Donehower1">[7]</xref>
###xml 505 508 505 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Purdie1">[9]</xref>
###xml 632 636 632 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Attardi1">[10]</xref>
###xml 638 642 638 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Lozano1">[11]</xref>
###xml 785 789 785 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-VanDyke1">[12]</xref>
###xml 791 795 791 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Frese1">[13]</xref>
###xml 1305 1310 1305 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1396 1400 1396 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 2178 2182 2178 2182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Kim1">[15]</xref>
###xml 2307 2311 2307 2311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 346 351 <span type="species:ncbi:10090">mouse</span>
###xml 619 624 <span type="species:ncbi:10090">mouse</span>
###xml 691 696 <span type="species:ncbi:10090">mouse</span>
###xml 1322 1326 <span type="species:ncbi:10090">mice</span>
###xml 1705 1709 <span type="species:ncbi:10090">mice</span>
###xml 2053 2057 <span type="species:ncbi:10090">mice</span>
Mutational studies on human tumors have been very useful in defining which tumor suppressor genes are important in particular human cancer types. However, mechanistic studies of tumor suppressor function have been facilitated by the development of genetically engineered mice with tumor suppressor gene alterations. We and others have shown that mouse cancer models with germline p53 deficiency develop many types of tumors much earlier in their lifespans compared to their p53 competent counterparts [7]-[9]. Numerous new mechanistic insights into p53 tumor suppressor functions have been obtained by exploiting these mouse models [10], [11]. More sophisticated methods of manipulating the mouse genome have led to models that allow spatial and temporal regulation of gene expression [12], [13]. Some of the newer models allow somatic deletion or activation of p53 in specific tissues. Other models, discussed below, allow global activation or suppression of p53. The ability to inducibly turn p53 activity on or off provides a unique experimental flexibility in which p53 tumor suppressor function can be studied in short defined windows of time. An example is a recent paper by the Evan laboratory, which addressed the mechanisms of p53 tumor suppression function in an illuminating way. Christophorou et al. developed mice containing an inducible wildtype p53 allele on a p53 null background [14]. When wildtype p53 was transiently induced concurrent with ionizing radiation treatment, lymphoid and intestinal tissues were observed to undergo massive p53-induced apoptosis. However, no protection from subsequent radiation-induced lymphomagenesis was observed when compared to irradiated, non-induced mice, indicating the DNA damage response was dispensable for long-term prevention of tumors due to acute stress. However, if wildtype p53 was transiently induced 8 days post-irradiation, circumventing the acute damage response and instead allowing mutations to develop, significant protection from radiation-associated lymphomas was noted as these mice survived 50% longer. This protection was dependent on ARF, a protein that activates p53 in response to oncogenic stress [15]. Thus, the p53-mediated arrest response to oncogenic activation (even if short term) is critical for protection from cancer [14]. This study has been important in shifting our focus from the immediate DNA damage response mechanisms of p53 to the ARF-mediated oncogenic response of p53 when considering its primary cancer suppressive role.
###end p 6
###begin p 7
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 459 463 <span type="species:ncbi:10090">mice</span>
###xml 852 856 <span type="species:ncbi:10090">mice</span>
###xml 926 930 <span type="species:ncbi:10090">mice</span>
###xml 1066 1070 <span type="species:ncbi:10090">mice</span>
###xml 1221 1225 <span type="species:ncbi:10090">mice</span>
###xml 1305 1309 <span type="species:ncbi:10090">mice</span>
In this paper, we attempted to address aspects of p53 tumor suppressor function through a novel approach. Instead of generating p53 germline mutations, we generated mice that allow global somatic deletion of one or both copies p53 at any chosen time. We homozygously deleted p53 at various time points before, concurrent with, and up to four weeks after ionizing radiation and monitored for radiation-induced lymphomas. Surprisingly, all groups of irradiated mice exhibited roughly the same median time to lymphoma formation after deletion of p53 (and much sooner than p53 deleted non-irradiated controls). Thus, even retention of p53 for up to 4 weeks post-damage may confer little or no protection from early lymphomagenesis. Instead, a sustained p53 anti-oncogenic response is required. We also examined the kinetics of spontaneous tumorigenesis in mice deleted for both p53 alleles at different ages and compared these to mice with germline deletions in both p53 alleles. As expected, we found that somatic p53 deletion delayed onset of tumors compared to those mice with germline p53 deletions, consistent with the age when p53 was deleted. However, when median tumor latencies were adjusted for time post-deletion, mice deleted for p53 at 3 months of age showed a delay in tumorigenesis relative to mice deleted for p53 at 6 and 12 months of age. We conclude that oncogenically activated cells accumulate rapidly with age in a p53-independent fashion and that wildtype p53 likely acts as a critical final or near final line of defense in suppressing these oncogenically activated clones.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Somatic deletion of p53 in mouse tissues
###end title 9
###begin p 10
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1A</xref>
###xml 228 235 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1A</xref>
###xml 334 337 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Marino1">[16]</xref>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rosa26</italic>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Seibler1">[17]</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Seibler1">[17]</xref>
###xml 861 864 861 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 879 882 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 972 975 972 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 989 992 989 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 249 253 <span type="species:ncbi:10090">mice</span>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 883 887 <span type="species:ncbi:10090">mice</span>
To examine the effects of global p53 gene deletion at specific ages in mouse tissues, we employed the strategy outlined in Fig. 1A. We crossed two genetically engineered mice: "floxed" p53 mice and Rosa26-CreERT2 knock-in mice (Fig. 1A). Floxed p53 mice carry an intact wildtype p53 allele containing two loxP recombination sites (p53F/F) in introns 1 and 10 of p53 [16]. CreERT2 mice contain a knock-in, modified Cre recombinase ubiquitously expressed from the Rosa26 locus [17]. The modified Cre recombinase expressed from the CreERT2 allele is fused to a mutated form of the estrogen receptor that is non-responsive to estrogen but highly sensitive to the estrogen receptor antagonist 4-hydroxytamoxifen (a downstream metabolite of tamoxifen) rendering it inactive until the addition of ligand [17]. Thus, intraperitoneal injection of the progeny CreERT2-p53+/F or CreERT2-p53F/F mice with tamoxifen results in activation of the Cre recombinase and deletion of one (p53+/F) or both (p53F/F) p53 alleles spanning exons 2 through 10 in multiple tissues.
###end p 10
###begin title 11
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
CreERT2-p53F/F and CreERT2+/F mice display efficient p53 allele excision in many tissues after tamoxifen treatment.
###end title 11
###begin p 12
###xml 567 574 567 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 858 861 856 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 869 872 867 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1024 1027 1022 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1108 1111 1106 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1192 1195 1190 1193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1433 1436 1431 1434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1895 1898 1889 1892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1914 1917 1908 1911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 2064 2067 2054 2057 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 2083 2086 2073 2076 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 2129 2136 2119 2126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">Mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
###xml 965 969 <span type="species:ncbi:10090">mice</span>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
###xml 1580 1584 <span type="species:ncbi:381124">corn</span>
###xml 1918 1922 <span type="species:ncbi:10090">mice</span>
(A) Experimental design to generate mice that can inducibly and somatically delete p53 in many tissues. Floxed p53 alleles are represented by triangle flanked bars. Cre-excised p53 alleles are indicated by solo triangles. (B) Tamoxifen treatment of wildtype mice moderately elevates liver DNA mutation frequency. Three month C57BL/6 Big Blue Mice designed to measure mutation frequencies were treated with tamoxifen (five 1 mg daily injections) and sacrificed at 2 or 4 weeks post-injection and liver DNA subjected to the mutation frequency assay as described in the methods. Mutation frequencies are shown with or without tamoxifen injection (n = 3 for each time point, +/-standard error of the mean). (C) Tamoxifen injection of mice has little or no effect on survival compared to vehicle-injected wildtype mice. Tamoxifen injection of CreERT2 negative p53F/F and p53+/F mice (red curve, n = 23) showed similar Kaplan-Meier survival curves as wildtype uninjected mice (black curve, n = 55) and vehicle injected CreERT2-p53+/F mice (blue curve, n = 50). (D) PCR assays show that vehicle-injected CreERT2-p53+/F tissues exhibit no p53 allele excision, while all tamoxifen-injected CreERT2-p53+/F tissues show evidence of p53 allele excision. Upper panels show genotyping PCR where the upper band (F) is the larger non-excised floxed allele of p53 and the lower band (+) is the non-floxed wild type p53 allele from various CreERT2-p53+/F tissues. The lower panels show PCR fragments specific for the excised p53 allele (Delta). The left set of panels contain results from vehicle (corn oil) treated tissues while the right set of panels contain PCR results from tamoxifen treated tissues. Note that in the absence of tamoxifen there is no background p53 allele excision and that in the presence of tamoxifen all tissues show evidence of p53 allele excision. (E) Tamoxifen treatment of CreERT2-p53+/F and CreERT2-p53F/F mice results in efficient p53 allele excision (Delta) in some, but not all tissues. Southern blot analysis of genomic DNA from various CreERT2-p53+/F and CreERT2-p53F/F tissues was performed as described in the methods. Note that spleen and liver show efficient excision, lung and kidney show partial excision, while eye and brain show little evidence of excision.
###end p 12
###begin p 13
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Phillips1">[18]</xref>
###xml 679 683 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-deBoer1">[19]</xref>
###xml 914 920 914 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2-week</sub>
###xml 932 938 932 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4-week</sub>
###xml 1002 1009 1002 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1B</xref>
###xml 1178 1185 1178 1185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vehicle</sub>
###xml 1196 1208 1196 1208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">non-injected</sub>
###xml 1374 1381 1374 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1C</xref>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 355 370 <span type="species:ncbi:10090">transgenic mice</span>
###xml 489 493 <span type="species:ncbi:381124">corn</span>
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
###xml 535 540 <span type="species:ncbi:10090">mouse</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 996 1000 <span type="species:ncbi:10090">mice</span>
###xml 1044 1048 <span type="species:ncbi:10090">mice</span>
###xml 1165 1169 <span type="species:ncbi:10090">mice</span>
###xml 1368 1372 <span type="species:ncbi:10090">mice</span>
The use of tamoxifen as an inducer raised the issue of whether it could have p53-independent effects on tumorigenesis, since some studies had shown tamoxifen-induced pathology and DNA adduct formation in rodent livers [18]. To ascertain whether tamoxifen injection itself was mutagenic or carcinogenic in mice, we injected 3 month old Stratagene Big Blue transgenic mice with our standard tamoxifen injection regimen (five consecutive daily intraperitoneal injections of 1 mg tamoxifen in corn oil). The Big Blue mouse is a transgenic mouse that contains non-expressed bacterial selectable markers that can be used to quantify genomic mutation frequencies in well defined assays [19]. Two or four weeks after tamoxifen injection, livers were harvested from the treated mice and genomic DNA was analyzed in the Big Blue mutation assay. The resulting data indicate that tamoxifen treatment significantly increases (p2-week = 0.0089, p4-week = 0.032) liver mutation frequency by roughly two-fold in mice (Fig. 1B). However, we found that wildtype mice injected with tamoxifen at 3 months of age exhibit very similar survival curve dynamics (Tamoxifen treated wildtype mice versus pvehicle = 0.269, pnon-injected = 0.572), longevities (maximal lifespan of: tamoxifen control = 1119 days, vehicle control = 1162 days) and tumor susceptibilities as vehicle injected control mice (Fig. 1C). Thus, tamoxifen injection may lead to a modest increase in liver DNA mutation frequency but it does not affect overall longevity or tumor susceptibility.
###end p 13
###begin p 14
###xml 52 55 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 71 74 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 499 506 499 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1D</xref>
###xml 616 619 616 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 635 638 635 638 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 691 698 691 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g001">Fig. 1E</xref>
###xml 973 977 973 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Hameyer1">[20]</xref>
###xml 1079 1082 1079 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1098 1101 1098 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1242 1245 1242 1245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
###xml 1102 1106 <span type="species:ncbi:10090">mice</span>
###xml 1246 1250 <span type="species:ncbi:10090">mice</span>
To detect whether tamoxifen treatment of CreERT2-p53F/F and CreERT2-p53+/F mice was efficient in global excision of p53 throughout all tissue types, we injected several of these mice at three months of age and harvested a variety of tissues two weeks later. Examination of genomic DNA from multiple tissues of the tamoxifen-treated and non-treated mice by PCR analyses showed no evidence of background p53 allele excision in non-treated mice, but detectable excision in all tissues of treated mice (Fig. 1D). To obtain a more quantitative estimate of relative allele excision in individual tissues of the CreERT2-p53+/F and CreERT2-p53F/F treated mice, Southern blot analysis was performed (Fig. 1E). The Southern blots showed essentially complete excision of the p53 alleles in spleen and liver and moderate levels of excision of kidney and lung, and low levels of excision in brain, heart, and eye; similar to what had been reported previously in the Rosa26-CreERT2 line [20]. We examined the kinetics of tamoxifen-mediated p53 deletion in the livers and spleens of CreERT2-p53+/F and CreERT2-p53F/F mice and found significant deletion after just one day of injections (data not shown). Tamoxifen treatment of 3 and 12-month old CreERT2-p53F/F mice resulted in similar efficiencies of allele excision in each tissue examined, indicating that age does not affect allele excision frequency (data not shown).
###end p 14
###begin title 15
Effects of p53 allele deletion on radiation-induced lymphomagenesis
###end title 15
###begin p 16
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 528 535 528 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2A</xref>
###xml 615 618 615 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 881 884 881 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 907 914 907 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2B</xref>
###xml 1334 1337 1334 1337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1400 1407 1400 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2B</xref>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 722 726 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1239 1243 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
To examine the effects of a carcinogen on p53 tumor suppressor function, we assessed the effects of somatic p53 allele loss on radiation-induced lymphomagenesis. First, to show that p53 allele excision affects the p53-mediated apoptotic response to DNA damage, we performed TUNEL assays on tissue sections of irradiated spleens (5 hours after 5 Gy IR) from tamoxifen or vehicle-treated CreERT2-p53F/F mice. Tamoxifen-injected mice showed little evidence of apoptotic cells, consistent with the deletion of p53 in these tissues (Fig. 2A). In contrast, spleen sections from vehicle-injected and irradiated CreERT2-p53F/F mice exhibited high levels of apoptosis, indicating that the p53-mediated response was intact in these mice. Next, we examined p53 and p21 (CDKN1A) protein levels in the irradiated and mock-irradiated spleen tissues of tamoxifen treated and untreated CreERT2-p53F/F mice 5 hours post-IR (Fig. 2B). p21 is a target gene of activated p53 that is transcriptionally induced following DNA damage. We found that p53 protein was expressed at moderate to high levels in all tissues where p53 alleles were intact and at reduced levels where the p53 alleles were excised. As expected, p21 levels were only increased in spleens of mice treated with IR and where p53 was not excised. Radiation and tamoxifen treated CreERT2-p53F/F mice showed little or no increase in p21 levels, as expected (Fig. 2B).
###end p 16
###begin title 17
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Tamoxifen treatment of CreERT2-p53F/F mice before, during, and after IR demonstrates the role of p53 in suppressing carcinogen-induced tumorigenesis.
###end title 17
###begin p 18
###xml 90 93 90 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 127 130 127 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 831 834 831 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1007 1010 1007 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1025 1028 1025 1028 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1300 1303 1300 1303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1557 1560 1557 1560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1665 1668 1665 1668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1942 1945 1942 1945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 2071 2074 2071 2074 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:381124">corn</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
###xml 590 594 <span type="species:ncbi:381124">corn</span>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 650 654 <span type="species:ncbi:381124">corn</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
###xml 1036 1040 <span type="species:ncbi:10090">mice</span>
###xml 1266 1270 <span type="species:ncbi:10090">mice</span>
###xml 1304 1308 <span type="species:ncbi:10090">mice</span>
###xml 1541 1545 <span type="species:ncbi:10090">mice</span>
###xml 1669 1673 <span type="species:ncbi:10090">mice</span>
###xml 1772 1776 <span type="species:ncbi:10090">mice</span>
###xml 1946 1950 <span type="species:ncbi:10090">mice</span>
###xml 2075 2079 <span type="species:ncbi:10090">mice</span>
###xml 2123 2127 <span type="species:ncbi:10090">mice</span>
(A) Deletion of p53 prior to irradiation prevents robust apoptotic response in CreERT2-p53F/F mice. Three month old CreERT2-p53F/F mice were injected with tamoxifen or vehicle (corn oil) two weeks prior to treatment with 5 Gray ionizing radiation. Five hours after IR treatment, spleens were harvested and tissue sections subjected to TUNEL assays for apoptotic cells. Note strong apoptotic response in vehicle treated mice and greatly reduced apoptotic response in tamoxifen-treated mice. Panel to the right shows percentage of TUNEL positive cells in spleens from untreated mice (No Tx), corn oil injected and non-irradiated mice (vehicle, No IR), corn oil injected and irradiated mice (vehicle, IR), and tamoxifen injected and irradiated mice (TAM, IR). (B) The p53 damage response is abrogated in tamoxifen injected CreERT2-p53F/F mice subjected to IR. Spleens were harvested from non-irradiated (-IR) and irradiated (+IR), non-injected (-INJ) and injected (+INJ 0 or 2 weeks post-injection) CreERT2-p53F/F (+Cre) and p53F/F (-Cre) mice and Western blots performed on tissue lysates using p53, p21, and actin antibodies. Note that robust p53 and p21 expression indicative of a robust p53 response occurs only in irradiated but non-Cre expressing or non-injected mice. (C) Six week old CreERT2-p53F/F mice were subjected to 2.5 Gy ionizing radiation and were injected with tamoxifen either 2 weeks prior (n = 10), simultaneous with (n = 14), 2 weeks after (n = 11), or 4 weeks after (n = 13) IR exposure. Non-irradiated tamoxifen treated mice CreERT2-p53F/F are included as controls (n = 62). (D) Kaplan-Meier tumor-free survival curves of IR-treated CreERT2-p53F/F mice show similar lymphoma latency of lymphomas post injection while non-IR treated tamoxifen-injected mice showed more delayed tumorigenesis. (E) Natural logarithm of mortality rates fitted using the T4253H smoothing algorithm comparing Gompertz variables from CreERT2-p53F/F mice injected with tamoxifen at 2 weeks prior and 4 weeks after IR treatment and non-IR treated tamoxifen-treated CreERT2-p53F/F mice (x-axis in days). Note that the IR-treated mice exhibit high mortality whether or not p53 is present at the time of radiation.
###end p 18
###begin p 19
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 436 439 436 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Kemp1">[21]</xref>
###xml 786 789 786 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 990 993 990 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1123 1126 1123 1126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1217 1221 1217 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2:0</sub>
###xml 1232 1237 1232 1237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2:+2</sub>
###xml 1248 1253 1248 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2:+4</sub>
###xml 1368 1377 1368 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2C,D</xref>
###xml 1437 1444 1437 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2D</xref>
###xml 1528 1531 1528 1531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1598 1601 1598 1601 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1688 1695 1688 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2E</xref>
###xml 1775 1778 1775 1778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1968 1971 1968 1971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 2004 2011 2004 2011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g002">Fig. 2E</xref>
###xml 2240 2246 2240 2246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 2246 2250 2246 2250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 440 444 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 748 752 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
###xml 994 998 <span type="species:ncbi:10090">mice</span>
###xml 1302 1306 <span type="species:ncbi:10090">mice</span>
###xml 1532 1536 <span type="species:ncbi:10090">mice</span>
###xml 1602 1606 <span type="species:ncbi:10090">mice</span>
###xml 1779 1783 <span type="species:ncbi:10090">mice</span>
###xml 1972 1976 <span type="species:ncbi:10090">mice</span>
Experiments by the Evan laboratory performed with mice containing an inducible wildtype p53 allele showed that after a carcinogenic insult, p53 could delay cancer if activated several days after the insult rather than during the insult. This suggested that the immediate p53-mediated damage response was less important than the subsequent anti-oncogenic response in preventing the emergence of tumors [14]. Here, we used the CreERT2-p53F/F mice in a reverse manner. Rather than inducing p53, we deleted both p53 alleles at various time points before, during, or after 2.5 Grays of ionizing radiation (IR) treatment. This IR dose is sufficient to induce rapid lymphoma formation in mice without p53, but insufficient for early lymphomas in wildtype mice [21]. We injected the CreERT2-p53F/F mice with tamoxifen 2 weeks prior (-2), during (0), 2 weeks after (+2), and 4 weeks after (+4) whole body irradiation, ten to twelve mice for each cohort. Tamoxifen injected non-irradiated CreERT2-p53F/F mice were used as controls. Surprisingly, when adjusted for time post-tamoxifen injection, all four tamoxifen-treated CreERT2-p53F/F groups exhibited roughly the same median time to lymphoma formation and survival curves (p-2:0 = 0.140, p-2:+2 = 0.211, p-2:+4 = 0.696), considerably earlier than the control mice in which wildtype p53 was deleted, but without IR treatment (Fig. 2C,D). The steepness of the post-irradiation survival curves in Fig. 2D indicated very high mortality rates in tamoxifen treated and irradiated CreERT2-p53F/F mice compared to the tamoxifen-treated, non-irradiated CreERT2-p53F/F mice. Such high mortality rates were confirmed in Gompertz variable analyses shown in Fig. 2E, where only modest mortality rate differences were observed between CreERT2-p53F/F mice deleted for p53 2 weeks prior to or 4 weeks after IR treatment (p = 0.023). Both of these rates were dramatically higher than those for tamoxifen treated but non-irradiated CreERT2-p53F/F mice (p = 0.0016 and p<0.0001) (Fig. 2E). Thus, even if wildtype p53 is retained for up to four weeks after radiation, the time to lymphomagenesis is essentially the same as if p53 was absent during radiation. These results confirm the earlier data from Christophorou et al.[14] that an intact and immediate p53 DNA damage response is irrelevant to subsequent lymphoma susceptibility. However, our data indicate retention of p53 for even up to 4 weeks post-IR treatment may confer little or no protection from early lymphomagenesis. Thus, it seems that a sustained p53 anti-oncogenic response for months after the initial damage is required for full protection against early lymphomas.
###end p 19
###begin title 20
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Spontaneous tumorigenesis in mice with homozygous p53 allele deletion at 3, 6, and 12 months of age
###end title 20
###begin p 21
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 348 351 348 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 547 550 547 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 571 574 571 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 581 588 581 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g003">Fig. 3A</xref>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 707 710 707 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 857 860 857 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1106 1109 1106 1109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1207 1214 1207 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g003">Fig. 3B</xref>
###xml 1395 1398 1395 1398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3:6</sub>
###xml 1409 1413 1409 1413 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3:12</sub>
###xml 1424 1428 1424 1428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6:12</sub>
###xml 1547 1550 1547 1550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1695 1698 1695 1698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1789 1796 1789 1796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g003">Fig. 3C</xref>
###xml 1845 1848 1845 1848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 711 715 <span type="species:ncbi:10090">mice</span>
###xml 861 865 <span type="species:ncbi:10090">mice</span>
###xml 988 992 <span type="species:ncbi:10090">mice</span>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
###xml 1551 1555 <span type="species:ncbi:10090">mice</span>
###xml 1626 1630 <span type="species:ncbi:10090">mice</span>
###xml 1957 1961 <span type="species:ncbi:10090">mice</span>
To determine the effects of losing both p53 alleles at various ages, we tamoxifen treated CreERT2-p53F/F mice at 3, 6, and 12 months of age. These mice and control tamoxifen-treated p53F/F mice without the CreERT2 allele were then monitored over their lifespan and examined for kinetics of tumor incidence. Tumor-free survival curves of CreERT2-p53F/F mice injected with tamoxifen at 3, 6, and 12 months were compared with germline p53-/- mice (n = 62, 13, 18, and 72 respectively). As expected, tumors arise later in tamoxifen-treated CreERT2-p53F/F mice compared to p53-/- mice (Fig. 3A). The 3 month tamoxifen-injected CreERT2-p53F/F mice showed a median tumor incidence about 140 days later than the p53-/- mice and the two survival curves paralleled each other very closely. Surprisingly, the survival curve of the 6 month tamoxifen treated CreERT2-p53F/F mice overlapped the 3 month cohort (p = 0.598), and developed tumors at nearly the same mean age as the 3 month old floxed p53 mice (305 days for the 3 month cohort, 323 days for the 6 month group). The 12 month old tamoxifen-treated CreERT2-p53F/F mice developed tumors with a median incidence of 529 days. When we adjusted tumor-free survival (Fig. 3B) to the time of tamoxifen injection, it was clear that later excision of p53 (6 and 12 months) resulted in a reduced median tumor latency relative to excision of p53 at 3 months (p3:6 = 0.005, p3:12 = 0.014, p6:12 = 0.389). Moreover, the tumor-free survival curves increased in "steepness" in the later tamoxifen treated CreERT2-p53F/F mice, again suggesting an increase in mortality rates in the older treated mice. Comparison between the 3 month and 12 month treated CreERT2-p53F/F Gompertz variables confirmed increasing mortality rates with later injection (p = 0.0007, Fig. 3C). Thus, tumors in the later injected CreERT2-p53F/F cohorts exhibit a reduction in median and maximum tumor-free post-injection survival, suggesting that these mice have an increased accumulation of pre-neoplastic or neoplastic clones that require loss of p53 to allow full tumor progression.
###end p 21
###begin title 22
###xml 41 44 41 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Tumor-free survival curves of CreERT2-p53F/F mice injected with tamoxifen at 3, 6, and 12 months of age.
###end title 22
###begin p 23
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 374 377 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 473 476 473 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 691 694 691 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 892 895 892 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 987 990 987 990 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1029 1032 1029 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 896 900 <span type="species:ncbi:10090">mice</span>
###xml 991 995 <span type="species:ncbi:10090">mice</span>
###xml 1033 1037 <span type="species:ncbi:10090">mice</span>
(A) Kaplan-Meier survival curves are shown for germline p53-/- mice in black (n = 72), CreERT2-p53F/F mice injected with tamoxifen at 3 months in blue (n = 62), at 6 months in green (n = 13), and at 12 months in red (n = 18). (B) Tumor-free survival curves adjusted for time after tamoxifen injection. Line colors represent the same groups as in A. Note that the CreERT2-p53F/F mice injected with tamoxifen at 6 and 12 months of age exhibit a similar median survival as p53-/- mice and a reduced median survival compared to their 3 month injected counterparts. (C) Natural logarithm of mortality rates fitted using the T4253H smoothing algorithm comparing Gompertz variables from CreERT2-p53F/F mice injected with tamoxifen at 3, 6 and 12 months (x-axis in days) show a significantly increased mortality rate in the 12 month injected mice (p = 0.0007). (D) Tumor types observed in CreERT2-p53F/F mice treated with tamoxifen at 3 and 6 months are similar to those observed in germline p53-/- mice. In 12 month injected CreERT2-p53F/F mice, carcinomas show a modest increase and lymphomas a modest decrease.
###end p 23
###begin p 24
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 275 278 275 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 285 292 285 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g003">Fig. 3D</xref>
###xml 353 356 353 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 535 538 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Venkatachalam1">[22]</xref>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 539 543 <span type="species:ncbi:10090">mice</span>
When we performed necropsies and histopathology on the tumors of the various tamoxifen treated CreERT2-p53F/F mice, we found that 3 and 6 month treated mice developed primarily lymphomas and secondarily soft tissue sarcomas, at ratios of roughly 2-3:1, similar to that of p53-/- mice (Fig. 3D). In contrast, lymphomas in the 12 month treated CreERT2-p53F/F mice comprised only 43% of total tumors, and there were more soft tissue sarcomas and carcinomas (36 and 14% respectively). This is more consistent with tumor observations in p53+/- mice, where retention of one wildtype p53 allele promotes later tumors which are more mixed in type [22].
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 980 983 980 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1184 1187 1184 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 231 236 <span type="species:ncbi:10090">mouse</span>
###xml 415 420 <span type="species:ncbi:9606">human</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 674 679 <span type="species:ncbi:10090">mouse</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
###xml 1137 1141 <span type="species:ncbi:10090">mice</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
In this paper, our goal was to better understand p53 tumor suppressor functions by employing a novel experimental approach. Rather than examining the effects of p53 germline deletion, we chose to somatically delete p53 in multiple mouse tissues at varying ages and at varying times before, during, and after a carcinogenic insult. This approach more accurately mimics the late somatic p53 loss that often occurs in human sporadic tumors (though massive simultaneous deletion of p53 is admittedly artificial). The bi-allelic progeny of the CreERT2 Rosa26 knock-in and floxed p53 knock-in mice allowed a very precise temporal regulation of p53 deletion in most tissues of the mouse. We found that efficient deletion occurred within 24 hours of the first tamoxifen injection and that the age of injection had little effect on deletion efficiencies. While the p53 gene in tissues such as brain, heart, and eyes were inefficiently excised, the tissues most susceptible to tumors in p53-/- mice (lymphoid and mesenchymal tissues) were generally quite susceptible to p53 allele excision. The tumor types observed in the somatically deleted p53 mice were very similar to those observed in p53-/- mice. The results presented here suggest that the incomplete p53 allele deletion in some tissues has only marginal, if any, effects on overall tumor incidence in this model.
###end p 26
###begin p 27
###xml 320 323 320 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 665 672 665 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g003">Fig. 3C</xref>
###xml 804 810 804 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g004">Fig. 4</xref>
###xml 1348 1354 1348 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g004">Fig. 4</xref>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 954 958 <span type="species:ncbi:10090">mice</span>
###xml 1423 1427 <span type="species:ncbi:10090">mice</span>
The age-specific somatic p53 deletion experiments were designed to test whether the aging process affects p53 tumor suppressor functions. When p53 was homozygously deleted at 3, 6, and 12 months of age, median tumor latencies after p53 deletion were 171, 123, and 141 days, respectively, compared to germline deleted p53-/- mice with a 128 day median tumor latency. The 6 and 12 month post deletion tumor incidence curves were significantly different from those of the mice deleted for p53 at 3 months (p = 0.005 and 0.014, respectively). In addition to median tumor latencies being reduced in the older p53 deleted mice, mortality rates also accelerated with age (Fig. 3C). By these criteria, rates of tumor progression after p53 deletion appear to increase with age. As shown in the model presented in Fig. 4, we hypothesize that these effects are the result of age-associated accumulation and progression of oncogenically activated cell clones in the mice. At three months of age, few such clones have accumulated or progressed to a stage where they can form an immediate cancer once p53 is deleted. Therefore, tumor development is delayed and mortality rates are low after p53 excision. However, by 12 months, increased numbers of oncogenically activated clones have progressed and await only the inactivation of p53 to become fully malignant (Fig. 4). Based on the rapidity of post-deletion tumor latency in the older mice, it is likely that for some of these precancerous clones, oncogenic activation of wildtype p53 is the final or near-final barrier preventing conversion to a malignant tumor. When p53 is deleted, such clones transition to malignancy. Prior to p53 deletion oncogenic clones clearly accumulate and evolve in the presence of active wildtype p53, suggesting that the presence of p53 may have little or no effect on early neoplastic evolution, but its loss can certainly accelerate progression to malignancy.
###end p 27
###begin title 28
###xml 14 24 <span type="species:ncbi:111938">gatekeeper</span>
p53 acts as a gatekeeper by preventing progression of oncogenically activated cells to full malignancy.
###end title 28
###begin p 29
###xml 54 57 54 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 923 926 923 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1008 1011 1008 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">mice</span>
###xml 668 672 <span type="species:ncbi:10090">mice</span>
###xml 927 931 <span type="species:ncbi:10090">mice</span>
###xml 1012 1016 <span type="species:ncbi:10090">mice</span>
###xml 1229 1233 <span type="species:ncbi:10090">mice</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1592 1602 <span type="species:ncbi:111938">gatekeeper</span>
From left to right 20 month old wildtype p53 mice, p53F/F mice with intact p53 until 3 and 12 months of age, and 6 week old irradiated p53F/F mice are shown. All of these mice accumulate oncogenically activated clones with age, though irradiation greatly enhances the numbers of such clones. Oncogenically activated clones are represented by yellow (early stage oncogenic clones that are not yet capable of tumor formation) and orange (later stage oncogenic clones capable of tumor formation upon loss of p53) circles. These clones are held in check by wildtype p53, which prevents their progression to full malignancy. However, after the age of 20 months in wildtype mice, p53 functional activities decline, which could lead to malignant progression of one or more oncogenic clones (cancers indicated by red circle). When p53 is deleted by tamoxifen injection at 3, 6, or 12 months or following IR treatment in CreERT2-p53F/F mice, some oncogenic clones will progress to form a malignant cancer. For the p53F/F mice, the median and maximal tumor latencies following p53 deletion decrease with age or with carcinogenic insult. The relative tumor latencies are indicated by the length of the red vertical arrows. For the wildtype mice, since p53 activity is merely reduced, malignant progression is more delayed. The small graphs below each of the tumor bearing mice shows the shape of the survival curves for each cohort, indicating that tumor latencies and mortality rates depend on p53 functional status, age, or the presence of carcinogenic insult. Thus, p53 acts as a final or near-final gatekeeper keeping these oncogenic clones from progressing to full malignancy.
###end p 29
###begin p 30
###xml 153 156 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 293 296 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Fukasawa1">[23]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Taylor1">[24]</xref>
###xml 1011 1015 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Bouffler1">[25]</xref>
###xml 1017 1021 1017 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Fukasawa2">[26]</xref>
###xml 1296 1300 1296 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Mao1">[27]</xref>
###xml 1301 1305 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Rubbi1">[29]</xref>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 885 889 <span type="species:ncbi:10090">mice</span>
###xml 1006 1010 <span type="species:ncbi:10090">mice</span>
One interesting result in these analyses was that the 3 month p53 deleted mice had a significant delay in median tumor incidence relative to germline p53-/- mice (p = 1.24x10-7), whereas the 6 and 12 month homozygous deletion incidence curves were not significantly different from germline p53-/- mice (p = 0.987 and 0.247, respectively). As one potential explanation for the tumor latency differences between the p53-/- and 3 month p53 deleted mice, we hypothesize that p53 has a significant protective effect on genomic integrity during embryogenesis and early postnatal development, when cell division rates are high and prone to potential chromosomal abnormalities. p53 has known roles in G2/M and mitotic spindle checkpoints and centrosome integrity and its absence would be expected to increase frequencies of chromosomal missegregation [23], [24]. Indeed, 4-6 week old p53 null mice have dramatically higher fractions of aneuploid cells in bone marrow, lymphoid and other tissues compared to normal mice [25], [26]. Thus, early in life the presence of p53 may protect against genomic instability that might facilitate formation of oncogenic clones, whereas later in life it protects against progression of oncogenic clones, as hypothesized in some models for p53 tumor suppressor function [27]-[29].
###end p 30
###begin p 31
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Feng1">[30]</xref>
###xml 645 651 645 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g004">Fig. 4</xref>
###xml 859 862 859 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1147 1151 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-GarciaCao1">[31]</xref>
###xml 1152 1156 1152 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Maier1">[34]</xref>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 985 989 <span type="species:ncbi:10090">mice</span>
These experiments also suggest that wildtype p53 cannot eliminate all oncogenic clones through apoptosis or keep them permanently arrested through senescence. Instead, activated wildtype p53 merely holds some of these oncogenic clones in stasis, suppressing their further malignant evolution only as long as p53 remains functional. Changes in p53 function may also explain in part why tumor incidence in wildtype mice rises dramatically with age. Levine and colleagues have recently demonstrated that p53 DNA damage responses, transcriptional activities and apoptotic functions decline significantly in older mice [30]. As shown in the model in Fig. 4, reduced p53 activity in older p53 wildtype mice could enhance progression of oncogenically activated clones to malignancy, but this progression would not be nearly as rapid as in the somatically deleted p53F/F mice, where p53 loss is immediate and complete. Moreover, the recently described cancer resistant transgenic and knock-in mice that express additional copies or more active versions of p53 could have more efficient suppression of oncogenically activated cell clones late into old age [31]-[34].
###end p 31
###begin p 32
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 856 860 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Christophorou1">[14]</xref>
###xml 361 365 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 985 989 <span type="species:ncbi:10090">Mice</span>
###xml 1251 1255 <span type="species:ncbi:10090">mice</span>
###xml 1312 1316 <span type="species:ncbi:10090">Mice</span>
###xml 1438 1442 <span type="species:ncbi:10090">mice</span>
Agents that induce acute DNA damage are often carcinogenic. The capacity for p53 to respond to both DNA damage and aberrant oncogenic signals suggested that both activities might be important in its tumor suppressor function following a carcinogenic insult such as ionizing radiation treatment. However, Christophorou et al.[14] showed in recent experiments on mice expressing an inducible wildtype p53 allele that the immediate p53 DNA damage response was irrelevant to prevention of radiation-induced lymphomas. Instead, the ARF-dependent p53 response to oncogenic activation was critical for delaying lymphomagenesis. Here, rather than activating p53 following treatment of mice with ionizing radiation, we deleted p53 at various time points before, concurrent with, and after irradiation. In many ways, our results confirm those of the Evan laboratory [14]. Whether or not wildtype p53 was present at the time of radiation treatment had no effect on subsequent lymphoma incidence. Mice in which p53 was deleted before, during, or after IR treatment displayed the same lymphoma latency. Surprisingly, however, we found that retention of wildtype p53 for as long as four weeks post IR treatment conferred no additional protection from lymphoma than mice that were deleted for p53 two weeks prior to radiation. Mice in which p53 was deleted four weeks after IR treatment showed the same median lymphoma latency and mortality rate as did mice in which p53 was deleted two weeks before irradiation (p = 0.696), relative to when p53 was deleted. This indicates that sustained wildtype p53 function is critical for suppressing tumorigenesis and that p53 may only keep some oncogenically activated cells in check rather than permanently disable or destroy them. This absence of wildtype p53 protective effect for up to four weeks post-IR that we observed differed from that observed by the Evan group, who showed that even a short six day activation of wildtype p53 eight days post-IR resulted in a significant delay in tumorigenesis. The reasons for the discrepancies are unclear, though they may be due to different features of the two models or that the Evan p53-ER fusion protein was a more robust tumor suppressor being activated in a cellular environment previously missing p53 entirely.
###end p 32
###begin p 33
###xml 386 392 386 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006654-g004">Fig. 4</xref>
###xml 66 76 <span type="species:ncbi:111938">gatekeeper</span>
These studies support a model in which p53 acts as a "progression gatekeeper" preventing oncogenically activated cell clones from becoming fully malignant. Such cell clones progress and increase in numbers with age and p53 may act as a final or near final line of defense against cancer. It is only with old age that p53 anti-cancer function may decline and cancers may finally emerge (Fig. 4). We have also confirmed that the acute DNA damage response of p53 is likely to be unimportant and that a long term continuous p53 response to oncogenically activated cells is likely to be critical for cancer suppression. While p53 may prevent cancer progression by inducing apoptosis or senescence in some oncogenically activated cells, for other such clones it merely prevents further malignant evolution. The somatic p53 deletion model presented here has been a source of useful insights into p53 tumor suppressor function and it may provide additional insights through further experimental manipulations.
###end p 33
###begin title 34
Materials and Methods
###end title 34
###begin title 35
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 35
###begin title 36
Ethics Statement
###end title 36
###begin p 37
All animals were handled in strict accordance with good animal practice as defined by the Institutional Animal Care and Use Committee for Baylor College of Medicine and Affiliates (Animal Protocol AN336) and by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC), Guide for the Care and Use of laboratory Animals (NRC1996).
###end p 37
###begin p 38
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Marino1">[16]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Seibler1">[17]</xref>
###xml 574 577 574 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 639 642 639 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 890 938 890 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Guide for the Care and Use of Laboratory Animals</italic>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 85 90 <span type="species:ncbi:10090">Mouse</span>
###xml 101 106 <span type="species:ncbi:9606">Human</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 708 712 <span type="species:ncbi:10090">mice</span>
FVB.129 doubly floxed (p53F/F) mice were obtained from the National Cancer Institute Mouse Models of Human Cancers Consortium and were originally generated by Anton Berns as previously described [16]. These mice were backcrossed into a C57BL/6 background. C57BL/6.SLJ CreERT2 homozygous mice were obtained from Artemis Pharmaceuticals GmbH [17] and backcrossed into a C57BL/6 background. C57BL/6 Big Blue mice were obtained from Stratagene (Austin, TX). All mice were bred and maintained in a specific pathogen-free animal facility at Baylor College of Medicine. CreERT2-p53F/F mice were generated by successive crossing of CreERT2 and p53F/F mice and genotyping by PCR as described below. All research with mice has been conducted in compliance with the Baylor Animal Protocol Committee (Baylor College of Medicine Animal Protocol AN336) and AAALAC recommendations as published in the The Guide for the Care and Use of Laboratory Animals (NRC1996).
###end p 38
###begin title 39
Allele genotyping
###end title 39
###begin p 40
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Dumble1">[35]</xref>
###xml 279 318 279 318 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAG AAC CTG ATG GAC ATG TTC AGG G-3&#8242;</named-content>
###xml 330 365 330 365 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCA GAC CAG GCC AGG TAT CTC T-3&#8242;</named-content>
###xml 515 547 515 547 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AAG GGG TAT GAG GGA CAA GG-3&#8242;</named-content>
###xml 562 594 562 594 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAA GAC AGA AAA GGG GAG GG-3&#8242;</named-content>
###xml 846 881 846 881 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAC AAA AAC AGG TTA AAC CCA G-3&#8242;</named-content>
High molecular weight genomic DNA was prepared from 5 mm tail tips or 50 mg tissue and prepared as previously described [35]. All PCR primers were synthesized by Integrated DNA Technologies (Coralville, IA). The presence of the CreERT2 gene was verified using the primers Cre-F: 5'-AAG AAC CTG ATG GAC ATG TTC AGG G-3' and Cre-R: 5'-CCA GAC CAG GCC AGG TAT CTC T-3', which produce a 790 bp product following standard PCR. Genotyping for the floxed p53 allele was performed using primers in p53 intron 10, Int10FOR: 5'-AAG GGG TAT GAG GGA CAA GG-3' and Int10REV: 5'-GAA GAC AGA AAA GGG GAG GG-3'. Using these primers, wildtype p53 alleles produce a 431 bp fragment, while the floxed p53 allele produces a 584 bp fragment following PCR. Successful excision of exons 2-10 by Cre recombinase was verified with PCR using primers Int10REV and Int1FOR (5'-CAC AAA AAC AGG TTA AAC CCA G-3').
###end p 40
###begin title 41
p53 allele deletion
###end title 41
###begin p 42
###xml 512 515 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 531 534 527 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 882 884 868 870 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1008 1039 994 1025 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5-CTA CCT GAA GAC CAA GAA GG-3&#8242;</named-content>
###xml 1054 1086 1040 1072 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGG AGG ATA TGG ACC CTA TG-3&#8242;</named-content>
###xml 1429 1432 1415 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1448 1451 1434 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 1598 1601 1584 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/F</sup>
###xml 1617 1620 1603 1606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 103 107 <span type="species:ncbi:381124">corn</span>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 894 899 <span type="species:ncbi:10090">mouse</span>
Tamoxifen (Sigma Aldrich, St. Louis, MO) was prepared at a concentration of 10 mg/ml in 5% ethanol/95% corn oil (after first suspending in 100% ethanol). To activate the CreERT2 recombinase, CreERT2 allele-containing mice were injected intraperitoneally with 100 microl tamoxifen solution (1 mg tamoxifen per injection) daily for five consecutive days at the ages of 3, 6, and 12 months for aging cohort experiments. To quantitate the relative efficiency of p53 allele deletion in specific tissues of CreERT2-p53+/F and CreERT2-p53F/F mice, genomic DNA was purified as described above from 50 mg of each tissue and 5-10 microg of DNA was digested with 10 units of Bgl II (New England BioLabs, Ipswich, MA) for 16 hours at 37degreesC. The restricted DNA was subjected to electrophoresis in a 0.8% agarose gel and Southern blotted using standard methods. The blot was hybridized to a 32P-labeled mouse p53 exon 11 DNA probe prepared from wildtype genomic DNA with PCR fragments generated from primers Ex11FOR (5-CTA CCT GAA GAC CAA GAA GG-3') and Ex11REV (5'-TGG AGG ATA TGG ACC CTA TG-3'). After hybridization and washing of the Southern blot followed by autoradiography, the relative intensity of hybridization in the intact p53 allele (20 kb), the excised p53 allele (10 kb) and a p53 pseudogene (2 kb) was quantitated on a GE Molecular Dynamics phosphorimager. Relative efficiencies of excision in tamoxifen-treated CreERT2-p53+/F and CreERT2-p53F/F tissues could be determined after normalizing band intensities to the pseudogene band and to wildtype p53 bands in non-treated control CreERT2-p53+/F and CreERT2-p53F/F tissues.
###end p 42
###begin title 43
Western blotting
###end title 43
###begin p 44
###xml 96 103 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#176;</sup>
###xml 218 222 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Hinkal1">[36]</xref>
###xml 344 348 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Hinkal1">[36]</xref>
Freshly excised tissue samples were harvested, snap frozen in liquid nitrogen, and stored at -80degreesC until use. Tissues lysates were prepared by homogenization of approximately 50 mg tissue as previously described [36]. For Western blots, 75 microg tissue lysates were loaded per SDS-polyacrylamide gel and analyzed as previously described [36]. Antibodies to p53 (R-19) and p21 (F-5) were from Santa Cruz Biotechnology (Santa Cruz, CA). Actin antibodies were obtained from NeoMarkers (Fremont, CA).
###end p 44
###begin title 45
Big Blue mutation frequency assay
###end title 45
###begin p 46
###xml 601 606 597 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 608 612 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-Hinkal1">[36]</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 196 200 <span type="species:ncbi:381124">corn</span>
###xml 206 210 <span type="species:ncbi:10090">Mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
To determine the effects of tamoxifen on mutation frequencies, wildtype C57BL/6 Big Blue mice from Stratagene were injected daily for five consecutive days with 1 mg of tamoxifen in 100 microl of corn oil. Mice were sacrificed at two or four weeks after the first injection and high molecular weight genomic DNA was prepared from the livers of treated and non-treated animals. The determination of mutation frequencies in the liver DNA of tamoxifen treated and non-treated Big Blue mice was performed according to the manufacturer's guidelines and the methods have previously been described in Hinkal et al. [36].
###end p 46
###begin title 47
Lifespan analyses
###end title 47
###begin p 48
###xml 758 763 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 765 769 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006654-deMagalhaes1">[37]</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 151 155 <span type="species:ncbi:10090">Mice</span>
###xml 191 195 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 800 805 <span type="species:ncbi:10090">mouse</span>
All treated and non-treated mice were monitored on a daily basis for morbidity or death as previously described. Severely morbid mice were euthanized. Mice that died overnight and euthanized mice were subjected to gross necropsy and organs and tumor lesions were fixed in 10% neutral buffered formalin, paraffin embedded and hematoxylin and eosin slides prepared in the Veterinary Pathology Core at Baylor College of Medicine. Slides were examined and tumors were classified histopathologically as to type. Survival curve comparisons for each cohort of mice were performed using statistical software for Kaplan-Meier Survival Analysis with Tarone-Ware statistics (SPSS Inc, Chicago). Mortality rates were calculated and compared as described by de Magalhaes et al. [37]. Briefly, relative numbers of mouse deaths per tenth of each year were used to calculate the hazard of death with age. These data were compared to other cohort mortality rates on a natural log scale and slopes compared by t-test.
###end p 48
###begin title 49
Irradiation-induced lymphomagenesis
###end title 49
###begin p 50
###xml 92 95 92 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">Mice</span>
To assess the effects of p53 allele status on radiation-induced lymphomagenesis, CreERT2-p53F/F mice were treated with tamoxifen for 5 consecutive days as described earlier. 5-7 weeks old mice were subjected to 2.5 Grays whole body ionizing gamma-radiation using a Cesium-137 source (MDS Nordion GammaCell 40 Exactor) 2 weeks prior to, concurrent with, 2 weeks after, or 4 weeks after tamoxifen treatment. Mice were then regularly monitored for morbidity or death whence necropsies and tumor-free survival curves were performed as described above.
###end p 50
###begin title 51
TUNEL assay
###end title 51
###begin p 52
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F/F</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:381124">corn</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
For assessing the effects of p53 allele status on IR-induced apoptosis, 3 month old CreERT2-p53F/F mice were injected with tamoxifen (1 mg/day) or vehicle (corn oil) for 5 consecutive days. Three weeks after the first injection, mice were either left untreated or were exposed to 5 Grays whole body gamma-irradiation. At 5 h post-irradiation, spleens were harvested and fixed in 10% buffered formalin. Tissues were processed, paraffin embedded, and sections (5 microm) were cut at the Baylor College of Medicine Histology Core. Immunostaining for apoptosis was performed using the In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science, Indianapolis, IN) as per manufacturer's instructions. Sections were counterstained with DAPI (1 microg/ml) and imaged at 40xmagnification under a fluorescence microscope (Zeiss Axioplan2, Carl Zeiss MicroImaging GmbH) using appropriate filters. Fluorescein labeled cells were scored as positive for TUNEL staining. For each tissue section, at least 3 fields were counted and the average percentage of TUNEL positive cells from 3 spleens for every condition was plotted.
###end p 52
###begin p 53
We thank Alan Herron for help in the analysis of tumor histopathology and Scott Pletcher for help with statistical analysis of the survival curves.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Lessons from hereditary colorectal cancer.
###end article-title 55
###begin article-title 56
###xml 18 28 <span type="species:ncbi:111938">gatekeeper</span>
p53, the cellular gatekeeper for growth and division.
###end article-title 56
###begin article-title 57
###xml 31 36 <span type="species:ncbi:9606">human</span>
Shaping genetic alterations in human cancer: the p53 mutation paradigm.
###end article-title 57
###begin article-title 58
Tumor suppressor genes.
###end article-title 58
###begin article-title 59
The role of p53 in tumor progression.
###end article-title 59
###begin article-title 60
###xml 53 58 <span type="species:ncbi:9606">human</span>
Prognostic and predictive value of TP53 mutations in human cancer.
###end article-title 60
###begin article-title 61
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
###end article-title 61
###begin article-title 62
The impact of p53 and p73 on aneuploidy and cancer.
###end article-title 62
###begin article-title 63
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene.
###end article-title 63
###begin article-title 64
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Probing p53 biological functions through the use of genetically engineered mouse models.
###end article-title 64
###begin article-title 65
###xml 38 43 <span type="species:ncbi:10090">mouse</span>
The oncogenic roles of p53 mutants in mouse models.
###end article-title 65
###begin article-title 66
Cancer modeling in the modern era: progress and challenges.
###end article-title 66
###begin article-title 67
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Maximizing mouse cancer models.
###end article-title 67
###begin article-title 68
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
###end article-title 68
###begin article-title 69
The regulation of INK4/ARF in cancer and aging.
###end article-title 69
###begin article-title 70
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum.
###end article-title 70
###begin article-title 71
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
Rapid generation of inducible mouse mutants.
###end article-title 71
###begin article-title 72
Understanding the genotoxicity of tamoxifen?
###end article-title 72
###begin article-title 73
###xml 29 44 <span type="species:ncbi:10090">transgenic mice</span>
Spontaneous mutation in lacI transgenic mice: a comparison of tissues.
###end article-title 73
###begin article-title 74
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.
###end article-title 74
###begin article-title 75
###xml 14 18 <span type="species:ncbi:10090">mice</span>
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis.
###end article-title 75
###begin article-title 76
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
###end article-title 76
###begin article-title 77
Abnormal centrosome amplification in the absence of p53.
###end article-title 77
###begin article-title 78
Regulation of the G2/M transition by p53.
###end article-title 78
###begin article-title 79
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice.
###end article-title 79
###begin article-title 80
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Genomic instability and apoptosis are frequent in p53 deficient young mice.
###end article-title 80
###begin article-title 81
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Stochastic modelling of tumorigenesis in p53 deficient mice.
###end article-title 81
###begin article-title 82
###xml 9 13 <span type="species:ncbi:10090">mice</span>
P53 null mice: damaging the hypothesis?
###end article-title 82
###begin article-title 83
###xml 5 15 <span type="species:ncbi:111938">Gatekeeper</span>
p53: Gatekeeper, caretaker, or both? 25 Years of p53 Research.
###end article-title 83
###begin article-title 84
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations.
###end article-title 84
###begin article-title 85
###xml 12 16 <span type="species:ncbi:10090">mice</span>
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally.
###end article-title 85
###begin article-title 86
Delayed ageing through damage protection by the Arf/p53 pathway.
###end article-title 86
###begin article-title 87
###xml 11 15 <span type="species:ncbi:10090">mice</span>
p53 mutant mice that display early ageing-associated phenotypes.
###end article-title 87
###begin article-title 88
Modulation of mammalian life span by the short isoform of p53.
###end article-title 88
###begin article-title 89
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Generation and characterization of p53 mutant mice.
###end article-title 89
###begin article-title 90
Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging.
###end article-title 90
###begin article-title 91
###xml 47 51 <span type="species:ncbi:10090">mice</span>
The influence of genes on the aging process of mice: a statistical assessment of the genetics of aging.
###end article-title 91
###begin p 92
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 92
###begin p 93
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the National Institute for Aging (NIA) and from the Ellison Medical Foundation to L.A.D. G.H. was supported by an NIA training grant. N.P. was supported by a postdoctoral fellowship from AFAR/Ellison Medical Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 93

